Key result
Patients receiving hemodialysis had a significantly higher risk of gastroduodenal ulcer bleeding compared to matched controls (HR 5.24, 95% CI 4.67-5.86, p<0.001).
Why the study?
Does end-stage renal disease receiving hemodialysis increase the risk of gastroduodenal ulcer bleeding compared to matched controls?
Cohort (n=78,828)
Does end-stage renal disease receiving hemodialysis increase the risk of gastroduodenal ulcer bleeding compared to matched controls?
Hazard Ratio: 5.24 (95% CI 4.67–5.86)
Absolute Event Rate: 6.5% vs 1.3%
p-value: p=<0.001
Patients with end-stage renal disease receiving hemodialysis have a more than five-fold increased risk of gastroduodenal ulcer bleeding compared to matched controls, with diabetes, coronary artery disease, cirrhosis, and NSAID use acting as significant risk factors.
No takes yet. Share an insight, caveat, or question.
Supports heightened vigilance for ulcer bleeding in hemodialysis; extends observational risk data but leaves open prevention trials.
Luo et al. (2011) conducted a cohort in End-stage renal disease (n=78,828). Hemodialysis vs. Matched controls without kidney disease was evaluated on Occurrence of ulcer bleeding as the main diagnosis during hospital stay (HR 5.24, 95% CI 4.67-5.86, p=<0.001). Patients receiving hemodialysis had a significantly higher risk of gastroduodenal ulcer bleeding compared to matched controls (HR 5.24, 95% CI 4.67-5.86, p<0.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: